ASLAN Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
November 22, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, Nov. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals to Participate in Fireside Chat at the 12th Annual Jefferies London Healthcare Conference 2021
November 10, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
October 26, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
ASLAN004 met primary endpoint and key secondary efficacy endpoints in a Phase 1 Multiple-Ascending-Dose (MAD) trial in patients with moderate-to-severe atopic dermatitis (AD) On track to initiate...
ASLAN Pharmaceuticals Announces Scientific Collaboration With Dr Emma Guttman-Yassky on Identification of ASLAN004-Specific Biomarkers
October 22, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, Oct. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Announces KOL Event Series to Discuss Atopic Dermatitis Treatment Landscape and ASLAN004
October 18, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
- Management to host the first in a series of KOL webinars beginning Monday, October 25, 2021, at 10:00am ET - First patient in global, 300-patient Phase 2b study of ASLAN004 on track for enrolment...
ASLAN Pharmaceuticals Announces Expansion of Scientific Advisory Board With Appointment of Leading Global Experts in Dermatology and Immunology
October 14, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, Oct. 14, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis
September 27, 2021 06:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
- Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile - ASLAN004 achieved a statistically significant improvement (p<0.0251) versus...
ASLAN Pharmaceuticals to Participate in the 2021 Cantor Virtual Global Healthcare Conference
September 22, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif., and SINGAPORE, Sept. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Establishes Scientific Advisory Board Chaired by Distinguished Dermatology Expert Dr Lawrence Eichenfield
September 21, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK. Calif. and SINGAPORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative...